UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong product development and market strategy, with ZUSDURI outperforming JELMYTO and expanding into community practices. Despite increased expenses and net loss, the optimistic guidance for ZUSDURI and strategic transition plans to UGN-103 suggest positive future prospects. The Q&A section reinforces confidence in ZUSDURI's growth, despite management's cautious responses. The absence of negative financial surprises and steady product adoption supports a positive sentiment, likely leading to a stock price increase of 2% to 8%.
Key Financial Performance
ZUSDURI revenue $15.8 million in 2025, reflecting early launch dynamics. No year-over-year comparison provided as it was the launch year. Reasons for the revenue include early launch dynamics and working through reimbursement and operational steps.
JELMYTO net product revenue $94 million for the full year 2025, reflecting continued underlying demand growth. No specific percentage change year-over-year provided.
Total revenues $109.8 million for the year ended December 31, 2025, compared with $90.4 million in 2024, a 21% year-over-year increase. The increase was driven by the commercial launch of ZUSDURI and increased sales of JELMYTO.
Research and development expenses $67.1 million for the year ended December 31, 2025, compared with $57.1 million in 2024, a year-over-year increase. The increase was primarily driven by higher manufacturing costs for ZUSDURI, costs associated with Phase III trials for UGN-103 and UGN-104, and the acquisition of UGN-501, partially offset by lower clinical trial costs and regulatory expenses for ZUSDURI.
Selling, general and administrative expenses $155.1 million for the full year ended December 31, 2025, compared to $121.2 million for the full year 2024. The year-over-year increase was primarily driven by ZUSDURI commercial activities, including sales force expansion and increased commercial operation costs.
Net loss $153.5 million for the year ended December 31, 2025, compared with $126.9 million in 2024. The increase in net loss was attributed to higher operating expenses, including R&D and SG&A costs.
Cash, cash equivalents, and marketable securities $120.5 million as of December 31, 2025. No year-over-year comparison provided.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ZUSDURI launch: ZUSDURI generated $15.8 million in revenue in 2025, reflecting early launch dynamics. A permanent J-code effective January 1, 2026, has facilitated broader adoption. The product addresses a large market and has the potential to achieve over $1 billion in peak revenue.
JELMYTO performance: JELMYTO generated $94 million in revenue in 2025, reflecting continued demand growth. It is a more mature product with steady engagement.
Pipeline advancements: UGN-103 and UGN-104 are progressing through Phase III trials, with UGN-103 showing a 77.8% complete response rate in the UTOPIA trial. UGN-501 is in IND-enabling studies, with a Phase I trial planned for 2026.
Market penetration for ZUSDURI: ZUSDURI has 838 activated sites of care, 102 unique prescribers, and 32 repeat prescribers as of December 31, 2025. Over 95% of covered lives have open access to ZUSDURI.
Community-based adoption: Community-based urologists are increasingly adopting ZUSDURI following the permanent J-code implementation, which has normalized reimbursement processes.
Financial flexibility: The company refinanced its term loan with Pharmakon Advisors, securing $200 million in nondilutive capital to support operations and pipeline advancements.
Operational efficiencies: The company is scaling its commercial organization to support 8,500 urologists and improve conversion timelines for ZUSDURI from 45-60 days to 2-3 weeks.
Long-term growth strategy: The company is focused on disciplined execution, expanding peer-to-peer education, and increasing patient awareness initiatives to support ZUSDURI adoption.
Pipeline expansion: Plans to expand UGN-103 into high-grade NMIBC and adjuvant settings for intermediate-risk patients are underway, with regulatory alignment expected in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Debt Refinancing: The company refinanced its term loan with Pharmakon Advisors, increasing the loan facility to $250 million with a fixed interest rate of 8.25%. This increases financial flexibility but also adds long-term debt obligations, which could strain financial resources if revenue growth does not meet expectations.
ZUSDURI Launch Challenges: The early launch phase of ZUSDURI faced typical reimbursement and operational hurdles, including a 45-60 day conversion timeline for patient enrollment to dosing. While a permanent J-code has improved adoption, the product is still in its early stages, and broader uptake depends on overcoming these initial barriers.
Increased Operating Expenses: Operating expenses for 2026 are projected to rise significantly to $240-$250 million, driven by sales force expansion, life cycle management plans, and increased share-based compensation. This could pressure profitability, especially given the company's net loss of $153.5 million in 2025.
Pipeline Development Risks: The company is advancing multiple pipeline products, including UGN-103 and UGN-104, with significant R&D investments. Delays or failures in clinical trials or regulatory approvals could impact future revenue and financial stability.
Market Penetration Uncertainty: ZUSDURI's success depends on achieving significant market penetration in a large but underserved market. Physician adoption and patient awareness are critical, and any delays in these areas could hinder revenue growth.
Financial Losses: The company reported a net loss of $153.5 million in 2025, up from $126.9 million in 2024. Continued losses could limit the company's ability to invest in growth initiatives and meet financial obligations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ZUSDURI Revenue Projections: ZUSDURI is expected to achieve greater than $1 billion in peak revenue based on market penetration, pricing, and physician adoption assumptions.
ZUSDURI Launch Trajectory: The launch is unfolding as expected in early 2026, with a permanent J-code effective January 1, 2026, removing a key barrier to adoption and facilitating predictable patient access.
UGN-103 Development Timeline: UGN-103 is on track for an NDA submission in the second half of 2026, with potential FDA approval in 2027. The company is also exploring its use in additional bladder cancer settings.
UGN-104 Development Timeline: UGN-104 is progressing through Phase III trials, with enrollment expected to complete by the end of 2026.
UGN-501 Development Timeline: UGN-501 is undergoing IND-enabling studies, with plans to submit an IND and initiate a Phase I clinical trial in 2026.
JELMYTO Revenue Guidance: Net product revenues for JELMYTO in 2026 are expected to be in the range of $97 million to $101 million, reflecting a year-over-year growth rate of approximately 3% to 7%.
Operating Expenses Guidance: Full-year 2026 operating expenses are expected to range from $240 million to $250 million, driven by increased share-based compensation, sales force expansion, and life cycle management plans for UGN-103.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Do you have any commentary on patient enrollment forms and how it compares to JELMYTO? When might you provide guidance for ZUSDURI?
A:Management noted that since the permanent J-code became effective, there has been a step-up in key indicators like patient enrollment forms, new patient starts, and doses, surpassing JELMYTO's performance in February. They are tracking ahead of JELMYTO and are comfortable with their guidance. Formal guidance for ZUSDURI may be provided at least two quarters post the permanent J-code.
Q:What is the trend among repeat prescribers and feedback from prescribers who are not yet repeat prescribers?
A:There is steady growth in both new and repeat prescribers. Repeat prescribers gain confidence after positive patient experiences and reimbursement assurance. New prescribers are waiting for clean claim submissions and reimbursement before becoming repeat prescribers.
Q:When might UGN-103 be introduced into the market, and how will it be positioned relative to ZUSDURI?
A:UGN-103 is expected to be introduced in early 2028 after obtaining a permanent J-code. The goal is to transition to UGN-103 quickly to avoid confusion and ensure physicians and patients switch from ZUSDURI.
Q:What types of patients are currently leveraging ZUSDURI, and how might this shift over the year?
A:Physicians are using ZUSDURI for patients who recur early, have frequent recurrences, or should avoid another surgery. The permanent J-code has opened up utilization in community practices, and the mix of settings is shifting towards community use.
Q:What are the life cycle management opportunities for UGN-103, and how does adjuvant therapy resonate with patients?
A:UGN-103 is being considered for adjuvant therapy in intermediate and high-risk disease settings. While some physicians use it in adjuvant settings today, the focus is on promoting its use without surgery, as this differentiates it from competitors.
Q:How does the channel mix for ZUSDURI compare to JELMYTO, and what trends are emerging?
A:ZUSDURI's utilization is shifting from 60% hospital-based to a 50-50 mix between hospital and community settings, driven by the permanent J-code and increased community adoption.
Q:What are the expansion opportunities for ZUSDURI in high-risk disease, and could it be used in combination with other agents?
A:ZUSDURI is being explored for adjuvant trials in high-risk disease, particularly BCG unresponsive cases. While initial trials will focus on monotherapy, combinations with other agents are being considered for broader patient populations.
Q:What is the level of investment in promoting ZUSDURI, and how does it align with the transition to UGN-103?
A:The company is fully investing in ZUSDURI as if UGN-103 does not exist, ensuring maximum opportunity and building a foundation for UGN-103. Resources are being allocated aggressively, including targeted patient engagement.
Q:What is the timeline to peak sales for ZUSDURI, and what happens after peak sales?
A:The timeline to peak sales is estimated at 4 years, with continued efforts to sustain growth and transition to UGN-103.
Q:How does RTGel technology differentiate UGN-501, and is a primer needed to activate the virus?
A:RTGel technology may provide longer dwell time, potentially enhancing efficacy and obviating the need for additional interventions like primers. This is under investigation.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical data for patient enrollment forms and ZUSDURI guidance, citing early launch stages and variables affecting uptake. They also used cautious language and avoided direct answers regarding adjuvant therapy usage and peak sales projections.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Director Investor
FDA approval
III enrollment
IND
Investor Relations
Kaplan Meier
Meier estimate
Pharma
Pharmakon
Phase III
Physicians
Senior Director
UGN grade
adult grade
cancer potential
capital
conversion
dose regimen
enrollment end
feedback
grade NMIBC
indicator
life cycle
manner
month Kaplan
pathway
peer
procedure
rate month
refinancing
repeat prescribers
step
track
trajectory
treatment option
URGN Transcript
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call summary indicates strong product development and market strategy, with ZUSDURI outperforming JELMYTO and expanding into community practices. Despite increased expenses and net loss, the optimistic guidance for ZUSDURI and strategic transition plans to UGN-103 suggest positive future prospects. The Q&A section reinforces confidence in ZUSDURI's growth, despite management's cautious responses. The absence of negative financial surprises and steady product adoption supports a positive sentiment, likely leading to a stock price increase of 2% to 8%.
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents mixed signals. Financial performance shows increased expenses and losses, while product development highlights potential growth with new launches and trials. However, the Q&A reveals delays and uncertainties in revenue recognition and adoption, impacting short-term expectations. The lack of clear guidance on demand and revenue timelines, coupled with financial losses, outweighs the positive aspects, leading to a negative sentiment.
UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript
Unknown8-9
The earnings call summary presents a mixed picture. Financial performance is weak due to a widening net loss, but the company has a strong balance sheet. Product development is positive with ongoing trials and new acquisitions, yet market strategy faces hurdles like reimbursement issues. The Q&A highlights management's optimism but lacks concrete metrics, which may concern investors. The absence of short-term guidance adds uncertainty. Despite potential in new drugs, the immediate outlook is uncertain, balancing positive long-term prospects with short-term challenges, resulting in a neutral sentiment.
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2025 Earnings Call Transcript
Unknown5-13
The earnings call reveals several concerns: missed EPS expectations, significant net loss, increased expenses, and no shareholder return plan. Despite optimistic guidance and strategic initiatives, these financial challenges and potential regulatory risks overshadow the positives. The Q&A session did not alleviate concerns, with some unclear responses. Given these factors, the stock is likely to experience a negative reaction in the short term.
URGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
